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Abstract
Background: Preterm  labour is the main cause of perinatal morbidity and mortality in the 
W estern  world. A t present, the re  is evidence that tocolysis for 48 hours is useful in women with 
threatened preterm  labour at least before 32 weeks. This allows transfer of the patient to  a 
perinatal centre, and maximizes the effect of corticosteroids for improved neonatal survival. It is 
questionable w hether trea tm en t with tocolytics should be maintained after 48 hours.
Methods/Design: The APOSTEL II trial is a m ulticentre placebo-controlled study. Pregnant 
women admitted for threatened preterm  labour w ho have been trea ted  with 48 hours 
corticosteroids and tocolysis will be eligible to  participate in the trial between 26+0 and 32+2 weeks
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gestational age. They will be randomly allocated to  nifedipine (intervention) o r  placebo (control) 
for twelve days o r  until delivery, w hatever comes first.
Primary outcom e is a com posite of perinatal death, and severe neonatal morbidity up to  evaluation 
at 6 months after birth. Secondary outcom es are gestational age at delivery, num ber of days in 
neonatal intensive care and total days of the first 6 months out of hospital. In addition a cost- 
effectiveness analysis will be perform ed. Analysis will be by intention to  treat. The pow er 
calculation is based on an expected 11% difference in adverse neonatal outcom e. This implies that 
406 women have to  be randomised (two sided test, P 0.2 at alpha 0.05).
Discussion: This trial will provide evidence as to  w hether maintenance tocolysis reduces severe 
perinatal morbidity and mortality in w om en with threatened preterm  labour before 32 weeks.
Trial Registration: Clinical trial registration: http://www.trialregister.nl, NTR 1336, date of 
registration: June 3rd 2008.
Background
Preterm birth is the most common cause of neonatal m or­
bidity and death worldwide [1]. Two thirds of the preterm 
births occur as a result of spontaneous labour beginning 
with spontaneous contractions or with preterm rupture of 
membranes. Preterm birth accounts for approximately 
75% of all neonatal deaths and 50% of childhood neuro­
logical morbidities [2]. Moreover, it is associated with 
high immediate and long-term costs after discharge from 
the hospital [3]. These include costs for special education 
services and institutionalised care for physically and m en­
tally disabled infants [4]. The prevalence of adverse neo­
natal outcome is strongly related to gestational age at 
delivery and declines from 77% at 24-27 weeks to less 
then 2% at 34 weeks and beyond [5]. Perinatal death and 
morbidity are not only strongly related to early gestational 
age but also to whether or no t antenatal corticosteroids 
are administered [6] and whether a preterm infant is 
transferred to a tertiary care centre before or after birth. 
Postponing delivery for 48 hours with tocolytics in order 
to allow maximal effect of maternal parenteral steroid 
administration and transfer of the mother to a centre with 
Neonatal Intensive Care Unit (NICU) facilities is therefore 
standard treatment in women with the diagnosis of 
threatened preterm labour before 32 weeks gestational 
age [7].
Approximately 75% of women with a diagnosis of threat­
ened preterm labour have not delivered after the first 48 
hours of tocolytic therapy with nifedipine. After this 48 
hour period the risk of preterm delivery persists. Two 
weeks after treatment for threatened preterm labour with 
nifedipine 65% of women are still pregnant [8].
Fetal fibronectin can be helpful in selecting women at risk 
for preterm delivery. Management based on knowledge of 
fetal fibronectin results significantly reduces preterm 
delivery less than 37 weeks compared to management 
without knowledge of these results (RR 0.54, 95% confi­
dence interval 0.34 to 0.87). However the incidence of 
preterm delivery less than 34, 32 and 28 weeks were sim­
ilar in both groups [9].
In national and international guidelines, a uniform treat­
m ent of threatened preterm delivery after 48 hours of toc­
olytic therapy has not yet been developed. Some 
obstetricians maintain tocolytic therapy until term, 37 
weeks gestational age, whereas others stop tocolytics after 
48 hours irrespective of gestational age or continue until 
for example 28 weeks gestational age. Maintenance treat­
m ent with several tocolytic agents has been being carried 
out in daily practice and include betamimetics [10,11], 
magnesium sulphate, indomethacin and calcium channel 
blockers [12] in order to achieve further prolongation of 
pregnancy and improvement of neonatal outcome. At 
present, no beneficial effect on perinatal outcome of such 
prolonged treatment has been established [13]. On one 
hand, tocolytic maintenance therapy with calcium chan­
nel blockers might be beneficial due to a positive effect on 
gestational age and possibly on neonatal outcome. O n the 
other hand, use of tocolytics is associated with rare but 
severe side effects on m other and child [14,15], and may 
increase the risk of some perinatal complications - includ­
ing intra-uterine infection.
Two systematic reviews included in DARE [16,17] and the 
Cochrane systematic review on maintenance tocolysis 
with nifedipine [12] reported only a few studies on the 
subject, and no reliable statement on the effectiveness of 
tocolytic maintenance therapy (TMT) on neonatal out­
come. Although nifedipine maintenance therapy may 
increase gestational age at delivery, there has been no 
improvement in neonatal or maternal outcome [18-20].
In summary, preterm delivery is an im portant health care 
problem. Whereas it is evident that tocolysis with admin­
istration of corticosteroids for 48 hours is effective, there 
is insufficient evidence for a uniform policy after these 48
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hours. In this randomised clinical trial we will investigate 
the effectiveness of maintenance therapy with nifedipine 
compared to placebo therapy in women with a gestational 
age below 32 weeks. Additional data will be collected for 
post-hoc evaluation of the clinical relevance of cervical 
length measurement and the presence of fibronectin in 
cervical mucus prior to maintenance tocolytic therapy.
This study is conducted within the Dutch Obstetric Con­
sortium, a collaborative effort of obstetric clinics in  The 
Netherlands to perform clinical trials. All ten Dutch peri­
natal centres with NICU facilities will participate in this 
trial.
Methods/Design
Aims
The aim of this study is to evaluate the effectiveness of toc­
olytic maintenance therapy on perinatal outcome after 
initial standard 48-hours' tocolytic therapy in women 
with threatened preterm birth between 26+0-32+2 weeks 
gestational age. The outcome is measured in terms of neo­
natal mortality and composite neonatal morbidity 
(chronic lung disease, severe intraventricular haemor­
rhage, periventricular leucomalacia, proven sepsis and 
necrotising enterocolitis), gestational age at delivery and 
costs.
Participants/eligibility criteria
Women with threatened preterm delivery with a gesta­
tional age between 26+0 and 32+2 weeks who have not 
delivered after 48 hours of tocolytics and corticosteroids 
are eligible for participation in the APOSTEL II-trial. 
Women with both singleton and multiple gestations are 
included. We chose no t to include women with a gesta­
tional age between 24 and 26 weeks to prevent protocol 
violation (rescue tocolysis during study medication).
Maternal exclusion criteria are signs of intrauterine infec­
tion, placenta praevia, maternal disease requiring delivery 
(i.e. HELLP syndrome or preeclampsia), maternal hyper­
tension and contraindications for the use of nifedipine. 
Fetal exclusion criteria are signs of fetal distress (abnormal 
cardiotocogram, abnormal biophysical profile), serious 
congenital defects and intrauterine death.
Procedures, recruitment, randomisation and collection o f  
data
The research nurse and/or the staff of participating hospi­
tals will identify eligible women. After the patient has 
given informed consent for participation in  the study, she 
is randomised using an internet-based procedure. Ran­
domisation is 1:1 for nifedipine or placebo.
At study entry baseline demographics, obstetric and med­
ical history are recorded. For post-hoc analysis on a subset
of women, at study entry cervical length is measured by 
transvaginal ultrasound and a vaginal swab is taken for 
fibronectin testing. Fibronectin will not be tested in 
women with ruptured membranes, more than 3 cm dila­
tation or vaginal bleeding. Fibronectin swabs are stored 
and analyzed after the patient has delivered. All data are 
collected, coded and processed with adequate precautions 
to ensure patient confidentiality.
Interventions
Patients are allocated to nifedipine or placebo for twelve 
days. Start of study medication is 48 hours after start of the 
initial tocolysis. Initial tocolysis is provided according to 
local protocol, usually this will be Nifedipine or Atosiban. 
Study medication consists of 20 milligrams nifedipine 
every six hours, administered orally, resulting in a total 
daily dose of 80 milligrams, or placebo. The medication is 
phased out from day 10 (total daily dose 60 milligrams 
nifedipine) till day 12 (total daily dose 20 milligrams 
nifedipine) and discontinued on day 13.
After randomisation the medication package is stored by 
the patient herself. The administration of the study medi­
cation is noted in a schedule that is kept both by the 
patient and in her medical record. Non-compliance is 
defined as a delay in administration of studymedication 
of more than 6 hours.
Follow up o f women and infants
All details of delivery, maternal assessments and admis­
sions during pregnancy are recorded in an electronic case 
report form (CRF). Details of neonatal admissions are 
also recorded. Long-term follow up of children is depend­
ing on future funding.
Outcom e measures
The primary outcome measure is neonatal mortality and 
a composite of neonatal morbidity. The composite m or­
bidity rate contains chronic lung disease, severe intraven- 
tricular haemorrhage more than grade 2, periventricular 
leucomalacia more than grade 1, proven sepsis and necr- 
otising enterocolitis at six months after birth.
Secondary outcome measures are gestational age at deliv­
ery, birth weight, days on supported ventilation and addi­
tional oxygen, length of admission in neonatal intensive 
care, total days in hospital until three months corrected 
age and costs. Moreover, we will compare the number of 
days that each neonate surpasses outside the hospital 
within the first 6 months after the calculated term date.
Statistical issues
Sam ple size
The sample size is calculated based on an 11% reduction 
in the primary outcome 'composite neonatal morbidity',
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from 25% to 14%. Using a two-sided test with an alpha of
0.05 and a power of 0.80 we have to randomise 406 
patients (203 in each arm).
Data analysis
Data will initially be analysed according to the intention- 
to-treat method. First, the nifedipine and placebo groups 
will be compared. Relative risks and 95% confidence 
intervals will be calculated for the relevant outcome meas­
ures.
Planned subgroup analysis will be performed to assess the 
consistency of a treatment effect among various patient 
characteristics i.e. cervical fibronectin status, presence of 
ruptured membranes, multiple pregnancy as well as cervi­
cal length at study entry. We will test for interaction 
between these characteristics and treatment effect.
Interim analysis
An interim analysis will be performed after the follow up 
data of 100 and 200 women have been obtained. The 
analyses will be done by an independent Data and Safety 
Monitoring Committee (DSMC) that is no t aware of treat­
m ent allocation when they judge the data on effective­
ness. In case of patients reporting severe side-effects, the 
DSMC can order to disclose the label of these patients.
Econom ic evaluation
General considerations
The aim of the economic evaluation is to compare the 
optimality, in terms of costs and health effects, of mainte­
nance tocolysis with nifedipine versus placebo. As the 
clinical study is based on a superiority design (it is 
hypothesized that nifedipine decreases preterm birth), the 
proper economic evaluation design is a cost-effectiveness 
analysis (CEA): the optimal strategy will probably be 
dominant, i.e. better health outcomes and lower costs. 
The economic evaluation will be performed from a soci­
etal perspective.
Cost analysis
The process of care is divided into three cost stages (ante­
natal stage, delivery/childbirth, postnatal stage) and three 
cost categories (direct medical costs, direct non-medical 
costs and indirect costs). For each stage and each cost cat­
egory, costs are measured as the volumes of resources used 
multiplied by appropriate valuations (cost-per-unit esti­
mates, fees, national reference prices).
Volumes of health care resource use are measured pro­
spectively alongside the clinical study in all participating 
centres as part of the CRF.
Valuations of direct medical resources (unit costs) are esti­
mated comprising "true economic" costs, i.e. including
shares of fixed costs and hospital overheads. An analysis 
based on reimbursement fees is added. Direct medical 
resources used outside the hospital and direct non-medi­
cal volumes are valued using national reference prices. 
Indirect costs are quantified bu t remain unvalued. Study- 
specific costs are excluded from analysis.
Ethical consideration
This study has been approved by the ethics committee of 
the Academic Medical Centre Amsterdam (Ref. no. MEC 
07/286) and by the boards of management of all partici­
pating hospitals. The trial is registered in the Dutch Trial 
Register, NTR 1336, http://www.trialregister.nl, date of 
registration: June 3rd 2008.
Discussion
Preterm birth is responsible for approximately 75% of all 
neonatal deaths and 50% of childhood neurological m or­
bidities [2]. It is also associated with high immediate and 
long-term costs after discharge from the hospital [3].
To date, it is not clear whether prolonged treatment with 
nifedipine is effective in reducing adverse perinatal out­
come [12,13]. On the one hand, tocolytic maintenance 
therapy with calcium channel blockers may be beneficial 
due to its positive effect on gestational age. On the other 
hand, use of tocolytics is associated with rare bu t severe 
side effects on m other and child [14,15]. Moreover, pro­
longation of pregnancy may also increase the chance for 
some perinatal complications such as infection.
As far as we know, there are no similar ongoing studies 
that will report on the subject. Neither the ISRTCN index 
of trials (UK), nor IMPACT/PSANZ Perinatal Trials Regis­
try (Australian) or NIH Clinical Trial database (USA) 
report any trials regarding maintenance tocolysis. There is 
one ongoing study (NIFTY study) registered that com­
pares oral nifedipine with placebo, in women with single­
ton pregnancies between 24 and 34 weeks, with intact 
membranes and a positive fibronectin test, in whom a full 
course of corticosteroids has been completed. Primary 
outcome is prolongation of pregnancy for at least seven 
days. Secondary outcomes are duration and number of 
NICU admissions, and maternal and neonatal hospital 
costs. In this study, the sample size needed to detect a dif­
ference in neonatal morbidity or mortality between the 
groups was not calculated.
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